IBC MEETING SUMMARY

White Oak (WO) Institutional Biosafety Committee

Thursday, April 16, 2026

9:30AM – 12:30PM EDT

Meeting Location: Teams

Facilitator: Derek Ireland
Recorder: Adaobi Nwoka

VOTING MEMBERS			
A	Allard, Marc HFP	**P**	Lina, Taslima NCTR
A	Baer, Alan CBER	**P**	Linden, Sara CDRH
A	Bramhall, Elizabeth Comm. Member	**A**	Miller, Mayumi CVM
P	Debrabant, Alain CBER	**P**	Pandey, Ruchi CDRH
A	Gannavaram, Sreenivas CBER	**P**	Papafragkou, Efstathia (Efi) HFP
P	Ge, Beilei CVM	**P**	Perlman, Amanda Comm. Member
P	Inselman, Amy NCTR	**P**	Richter, Taylor HFP
P	Ireland, Derek CDER	**P**	Schwartzman, Louis OOSH
P	Khan, Saeed A. NCTR	**P**	Stantchev, Tzanko CDER
P	Khanna, Marilyn OCS/OSLA	**P**	Venkataraman, Thiagarajan (Raja) CBER
P	Kochan, Travis CBER	**A**	Verma, Anita CBER
P	Krishna, Ashok CDER	**P**	Waggener, Christopher T. HFP
P	Laassri, Majid CBER		

EX-OFFICIO MEMBERS & OPTIONAL ATTENDEES			
A	Aljazrawi, Aveen	**P**	Lien, Christopher OOSH
P	Brown, Tracey OOSH	**P**	Marth, Theresa HFP
A	Buttke, Thida OC	**A**	MacWilliams, Ziven OOSH
A	Degrasse, Jeffrey OOSH	**P**	McNeil, Ronald OOSH
P	Dixon, Jeremy OOSH	**P**	Perrine, Albert
A	Evans, Anissa Comm. Member for NCTR	**P**	Nwoka, Adaobi* OOSH
P	Fowler, Joe NCTR	**A**	Ragan, Angela OOSH
A	Hadden, Phoebe OOSH	**P**	Reid, Ericka CBER
P	Howard, Michele OOSH	**P**	Sanad, Yasser Comm. Member for NCTR
A	Kemp, Margaret CBER	**A**	Snyder, Jessica CDER
		A	Tremonti, Annette OC

P = Present; A = Absent; CBER = Center for Biologics Evaluation and Research; CDER = Center for Drug Evaluation and Research; CDRH = Center for Devices and Radiological Health; CVM = Center for Veterinary Medicine; FDA = U.S. Food and Drug Administration; HFP = Human Foods Program; NCTR = National Center for Toxicological Research; OC = Office of the Commissioner; OCS = Office of the Chief Scientist; OOSH = Office of Occupational Safety and Health; OSLA = Office of Science and Laboratory Advancement

IBC MEETING SUMMARY

White Oak (WO) Institutional
Biosafety Committee

Thursday, April 16, 2026
9:30AM – 12:30PM EDT
Meeting Location: Teams

ADMINISTRATIVE REVIEW APPROVALS

WO IBC Administrative Review Approvals Since 3/11/26		
App. #	**Title**	**Approval Date**
13227	Method Extension and U.S. Market Survey of Mycotoxins in Priority Food Commodities	04/09/2026
13184	Development of potency assays for gonadotropin hormones	04/07/2026
13186	Development of Multi-attribute characterization assay for anti-viral therapeutics	04/07/2026
13207	Bioanalysis of Human derived samples	03/26/2026
13091	Profiling RNA, protein and metabolite biomolecules in human biospecimens as potential biomarkers of drug response and toxicity	03/24/2026
13147	Identifying molecular and morphological features important for stem cell function	03/24/2026
11750	Interferon expression in response to Respiratory Syncytial Virus, Rhinovirus, Epstein Barr Virus, Adenovirus, or Cytomegalovirus, and Vesicular Stomatitis Virus	03/23/2026
13081	Studies on safety and efficacy of platelets and other transfused cellular blood products	03/19/2026
13179	Studying the impact of Chikungunya virus in regards to blood transfusion safety	03/18/2026
13159	Studies on hepatitis C virus	03/17/2026
13194	Assessment of the role of specific commensal bacteria in during gut infection	03/17/2026
13198	Investigation of biology of ZIKV infection and replication	03/17/2026

IBC MEETING SUMMARY

White Oak (WO) Institutional
Biosafety Committee

Thursday, April 16, 2026
9:30AM – 12:30PM EDT
Meeting Location: Teams

MEETING SUMMARY

I. Meeting Commencement:

- The WO IBC meeting commenced at 9:30 EDT.

II. Attendance

- A total of 19 voting members were present, which fulfilled the quorum needed to conduct IBC business.

III. Review of March 19, 2026, WO IBC Meeting Minutes:

- Derek Ireland motioned for approval of the March 19, 2026, Meeting Minutes and Louis Schwartzman seconded the motion.
- The March 19, 2026, meeting minutes were approved by 17 votes of approval, 2 votes of abstentions and 0 votes of disapproval.

IV. Applications

App. #	Title	Reviewer	NIH Ref	Outcome
13162	Novel use of porcine gastric mucin for concentration and infection of human norovirus	1. Primary Reviewer 2. Secondary Reviewer	NA	Approve ☒ Table ☐

*Approval is contingent upon full remediation of application, incorporating all reviewers' stipulations and requirements.

Application 13162 Project Overview:

Section A: Synopsis

- The goal of this study is to evaluate the use of mucin coated magnetic beads to capture and concentrate infectious human norovirus particles from berries. Infectivity of two norovirus strains belonging to the most epidemiologically important genogroups (GI and GII) will be assayed using the Human Intestinal enteroids system.

Section G: Pathogen and/or Toxin

- Norovirus

General Comments from Primary Reviewer:

The primary reviewers' recommendations are as follows:

- The application is well done, detailed and the practices such as working in a biosafety cabinet and decontamination steps along with PPE are well described. Many times, most of the protocols the applicant is using have been previously approved by past IBC applications. Therefore, the reviewer has no issues with this application and suggests approval.

General Comments from Secondary Reviewer:

The secondary reviewers' recommendations are as follows:

- Some limited information from the previously approved (IBC#12780) could be included here on the origin of the cells used
- The application is written with enough detail regarding safety considerations (containment, decontamination and appropriate training). This application can be approved once the minor comments are addressed. Some mention of where handling procedures such as vortexing, pipetting and mixing will take place would be useful. Lastly, some information on whether any screening for infectious agents has been done on the clinical samples may be useful to be included.
- Change Section E to "No" and remove all subsequent information in this section. The application references NIH Guidelines Section III-D-3-a; however, this protocol does not appear to involve recombinant or synthetic nucleic acid molecule work or use of helper systems.
- Please include some minor information from the previously approved (IBC#12780) describing the origin of the cells used. Very briefly describe the nature of the cells and their generation.
- Section A: Sonication is mentioned later in the document, but no details as to when and how it is used are provided here. Please describe the sonication methods in section A and list any safety measures used to prevent lab acquired viral infection.

Discussions and Questions During the IBC Meeting

- In Section E, the PI states they are doing recombinant work and references Section 3D3A of the recombinant guidelines regarding using risk Group 2 viruses as a helper system. It does not appear that they are doing recombinant work. The PI should change Section E to "No" and remove the 3D3A reference.

IBC Committee Recommendations for Application 13162:

- Primary reviewer motioned for approval of application 13162 with minor modifications. Secondary reviewer supported the motion.

- Application 13162 was approved by 19 votes of approval, 0 votes of disapproval, and 0 abstentions.

App. #	Title	Reviewer	NIH Ref	Outcome
13206	Single Laboratory Validation of BAM Salmonella culture and qPCR methods for large test portion sizes	1. Primary Reviewer 2. Secondary Reviewer	NA	Approve ☒ Table ☐

*Approval is contingent upon full remediation of application, incorporating all reviewers' stipulations and requirements.

Application 13206 Project Overview:

Section A: Synopsis

- In this application, PI is validating the *BAM Salmonella* species culture method and qPCR screening method for the detection of *Salmonella* species contamination in larger portion size food samples. PI hypothesize that a test portion size larger than the current portion size of 25g could provide a more representative result and a statistically higher chance of finding the target of interest related to an outbreak investigation.

Section G: Pathogen and/or Toxin

- Salmonella spp

General Comments from Primary Reviewer:

The primary reviewers' recommendations are as follows:

- The application is complete and covers all biosafety measures to be taken to avoid any exposure to researchers while handling the live *Salmonella* cultures except the concerns mentioned below.
    - Live Salmonella cultures will be centrifuged for concentration purposes. PI should include the precautions that will be taken to avoid the aerosol generation in this application.
    - The PI did not mention which species of *Salmonella* will be used in the experiment. Please include the species in section G.

General Comments from Secondary Reviewer:

The secondary reviewers' recommendations are as follows:

- This application poses minimal risk and there is nothing that stands out as potentially hazardous, however some specific details are missing and I recommend this application

be amended to include some of the details included above and a Spill response protocol for larger volumes.

- Live Salmonella cultures will be centrifuged for concentration purposes. PI should include the precautions that will be taken to avoid the aerosol generation in this application.
- The PI did not mention which species of *Salmonella* will be used in the experiment. Please include the species in section G
- Please clarify what is meant by "Broth (9 times sample weight)—This appears to be multiple liters of brain heart infusion broth?
- Please provide a Spill Response plan for larger volumes.
- Estimated Start date is listed as 4/1/2025, please change to today's date.
- Section G: Please clarify if Salmonella spp., strains will be kept for long term storage and if so, will they be stored in a -80C freezer?

Discussions and Questions During the IBC Meeting

- The PI states they will employ methods that have been validated for 25g and using those methods for 375g. The PI needs to verify that the application includes containment and spill procedures for large volume.

IBC Committee Recommendations for Application #13206:

- Primary reviewer motioned for approval of application with minor modifications. Secondary reviewer supported the motion.
- Application #13206 was approved by 19 votes of approval, 0 votes of disapproval, and 0 abstentions.

V. Meeting Adjournment: The IBC meeting was adjourned at 10:51 a.m. EDT.

VI. Next IBC Meeting: The next meeting is scheduled for May 21, 2026, at 9:30 a.m. EDT.